Μετάβαση στο περιεχόμενο

ΕτικέταMedImmune

Imfinzi significantly improves overall survival in the Phase III PACIFIC trial for unresectable Stage III non-small cell lung cancer

Imfinzi met the second primary endpoint of overall survival which was both statistically-significant and clinically-meaningful at a planned interim analysis AstraZeneca and MedImmune, its global biologics research and development arm, … Continue Reading Imfinzi significantly improves overall survival in the Phase III PACIFIC trial for unresectable Stage III non-small cell lung cancer